B. Riley Issues Negative Forecast for Harrow Earnings

Harrow, Inc. (NASDAQ:HROW) – Equities research analysts at B. Riley lowered their Q2 2025 EPS estimates for Harrow in a research note issued to investors on Monday, March 31st. B. Riley analyst M. Mamtani now forecasts that the company will post earnings per share of $0.17 for the quarter, down from their previous forecast of $0.25. B. Riley has a “Buy” rating and a $65.00 price objective on the stock. The consensus estimate for Harrow’s current full-year earnings is ($0.53) per share. B. Riley also issued estimates for Harrow’s Q3 2025 earnings at $0.21 EPS and Q4 2025 earnings at $0.38 EPS.

Harrow (NASDAQ:HROW) last posted its quarterly earnings data on Thursday, March 27th. The company reported $0.25 earnings per share for the quarter, topping the consensus estimate of $0.11 by $0.14. The firm had revenue of $66.83 million for the quarter, compared to analysts’ expectations of $66.01 million. Harrow had a negative return on equity of 45.57% and a negative net margin of 19.75%.

Separately, HC Wainwright reiterated a “buy” rating and set a $57.00 target price on shares of Harrow in a research report on Monday.

Harrow Stock Performance

NASDAQ HROW opened at $26.05 on Wednesday. The firm has a 50-day moving average price of $28.36 and a two-hundred day moving average price of $37.63. Harrow has a 12-month low of $9.86 and a 12-month high of $59.23. The company has a market capitalization of $927.77 million, a P/E ratio of -27.71 and a beta of 0.69. The company has a quick ratio of 1.44, a current ratio of 1.55 and a debt-to-equity ratio of 3.23.

Hedge Funds Weigh In On Harrow

Institutional investors have recently added to or reduced their stakes in the stock. GF Fund Management CO. LTD. bought a new stake in shares of Harrow during the fourth quarter worth $25,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its holdings in Harrow by 89.5% in the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 61,940 shares of the company’s stock valued at $2,078,000 after buying an additional 29,262 shares during the last quarter. Two Sigma Advisers LP boosted its position in Harrow by 30.4% during the 4th quarter. Two Sigma Advisers LP now owns 38,200 shares of the company’s stock worth $1,282,000 after buying an additional 8,900 shares during the period. Two Sigma Investments LP raised its stake in shares of Harrow by 483.2% during the fourth quarter. Two Sigma Investments LP now owns 150,355 shares of the company’s stock valued at $5,044,000 after acquiring an additional 124,574 shares during the last quarter. Finally, Rafferty Asset Management LLC acquired a new position in shares of Harrow during the fourth quarter worth $270,000. 72.76% of the stock is currently owned by institutional investors and hedge funds.

Harrow Company Profile

Harrow, Inc operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc and changed its name to Harrow Health, Inc in December 2018. Harrow Health, Inc was incorporated in 2006 and is headquartered in Nashville, Tennessee.